LifeMD (NASDAQ:LFMD) Stock Gets Price Target Cut from Lake Street Capital

LifeMD (NASDAQ:LFMD) had its price objective decreased by analysts at Lake Street Capital from $5.00 to $3.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Lake Street Capital‘s price target would indicate a potential upside of 36.67% from the company’s current price.

Other research analysts have also issued reports about the stock. Wall Street Zen lowered shares of LifeMD from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. BTIG Research lowered their price target on LifeMD from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Zacks Research upgraded LifeMD from a “strong sell” rating to a “hold” rating in a research report on Monday, August 17th. KeyCorp set a $5.00 price objective on LifeMD and gave the company an “overweight” rating in a research note on Friday, August 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of LifeMD in a research report on Thursday, September 17th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $7.14.

LifeMD Price Performance

Shares of LFMD stock traded up $0.54 during trading hours on Friday, hitting $2.19. The stock had a trading volume of 5,892,427 shares, compared to its average volume of 1,033,151. The firm has a market capitalization of $105.80 million, a PE ratio of -43.89 and a beta of 2.19. LifeMD has a twelve month low of $1.60 and a twelve month high of $5.38. The stock’s 50 day moving average is $2.62 and its 200 day moving average is $3.58.

LifeMD (NASDAQ:LFMD) last announced its earnings results on Thursday, November 12th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03. LifeMD had a net margin of 0.10% and a negative return on equity of 168.23%. The business had revenue of $44.63 million for the quarter, compared to analysts’ expectations of $48.84 million. As a group, equities analysts predict that LifeMD will post -0.48 earnings per share for the current year.

Hedge Funds Weigh In On LifeMD

A number of large investors have recently modified their holdings of the business. BlackRock Inc. lifted its holdings in shares of LifeMD by 8.0% in the 2nd quarter. BlackRock Inc. now owns 3,034,535 shares of the company’s stock valued at $12,533,000 after buying an additional 225,510 shares during the period. State Street Corp grew its holdings in LifeMD by 22.6% during the second quarter. State Street Corp now owns 1,318,784 shares of the company’s stock worth $5,447,000 after acquiring an additional 243,376 shares during the period. Walleye Capital LLC acquired a new position in LifeMD during the second quarter worth $1,338,000. Russell Investments Group Ltd. raised its position in LifeMD by 5,801.2% in the second quarter. Russell Investments Group Ltd. now owns 314,770 shares of the company’s stock worth $1,300,000 after acquiring an additional 309,436 shares in the last quarter. Finally, Bank of America Corp DE purchased a new position in LifeMD in the second quarter worth $1,078,000. 35.52% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting LifeMD

Investors following LFMD have been watching these stories:

• Positive Sentiment: LifeMD reported a Q3 loss of $0.11 per share, narrower than the consensus loss of $0.14. Adjusted EBITDA loss was about $0.4 million, within guidance and improved by roughly $3.1 million from Q2, partly due to lower selling, marketing, and other non-clinical expenses. LifeMD Reports Third Quarter 2026 Results
• Neutral Sentiment: Mizuho lowered its price target from $7 to $6 but maintained an “outperform” rating, signaling continued optimism despite the reduced target. Mizuho stock recommendations
• Negative Sentiment: Q3 revenue of $44.6 million missed the $48.8 million analyst estimate. The company also forecast Q4 revenue of $46–$49 million, versus a $61.4 million consensus, and FY2026 revenue of $188–$191 million, versus a $207.6 million consensus. The outlook gaps may weigh on expectations for near-term growth. LifeMD reports Q3 loss, misses revenue estimates

About LifeMD

LifeMD, Inc. is a virtual healthcare company that connects patients with medical providers through its telehealth platform. Its services include virtual primary care and specialty care, with offerings in areas such as men’s health and weight management. The company operates the LifeMD and Rex MD brands and supports care through online consultations, treatment plans and, when prescribed, medication. Service availability and treatment options may vary by state and individual patient needs. LifeMD serves patients in the United States.